Neoleukin Therapeutics, Inc.
NLTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $73,878 | $73,483 | $73,276 | $66,223 |
| - Cash | $71,005 | $58,813 | $70,771 | $136,586 |
| + Debt | $10,208 | $10,966 | $11,707 | $12,428 |
| Enterprise Value | $13,081 | $25,636 | $14,212 | -$57,935 |
| Revenue | $0 | $0 | $0 | $6,836 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $3,418 |
| % Margin | – | – | – | 50% |
| EBITDA | -$20,176 | -$26,081 | -$25,919 | -$62,544 |
| % Margin | – | – | – | -914.9% |
| Net Income | -$20,953 | -$22,016 | -$22,647 | -$48,424 |
| % Margin | – | – | – | -708.4% |
| EPS Diluted | -0.99 | -1.05 | -1.08 | 2.41 |
| % Growth | 5.7% | 2.8% | -144.8% | – |
| Operating Cash Flow | -$19,508 | -$19,462 | -$20,774 | -$49,252 |
| Capital Expenditures | -$127 | -$148 | -$780 | -$257 |
| Free Cash Flow | -$19,635 | -$19,610 | -$21,554 | -$49,509 |